Post-stroke orthostatic hypotension, its pattern of recovery

Poster PresentationINTRODUCTION: Orthostatic hypotension (OH) is common in stroke patients due to damage to central autonomic centres or pathways. Its pattern of recovery is not well defined. METHODS: First-ever stroke patients admitted to Queen Mary Hospital were recruited, excluded those with known cardiac illness or disorders that can affect ANS. 60° tilt table was performed in Tung Wah Hospital at 14 and 90 days post-stroke. NIHSS and BI were measured at 6-month follow-…published_or_final_versio

Impact of stroke on autonomic nervous system

INTRODUCTION: Disturbances of the autonomic nervous systems (ANS) are not uncommon in stroke patients, attributed to damage of the central autonomic networks. The resultant alternation in autonomic dynamics caused an imbalance between sympathetic and parasympathetic tone. The most common clinical problems include abnormalities in heart rate and blood pressure control. Vasomotor and sudomotor disturbances post stroke are less well defined …published_or_final_versio

Experience of using bevacizumab in epithelial ovarian, fallopian tube and primary peritoneal cancers in a single centre

Objectives: To review the use of bevacizumab in epithelial ovarian, fallopian tube and primary peritoneal cancers in our centre. Methods: Patients receiving bevacizumab for epithelial ovarian, fallopian tube and primary peritoneal cancer at the Division of Gynaecological Oncology, Queen Mary Hospital, The University of Hong Kong between January 2011 and December 2015 were included. A retrospective chart review was performed. Main outcome measures were adverse events and progression-free survival. Results: Overall, 41 patients received bevacizumab for epithelial ovarian, fallopian tube or primary peritoneal cancer, of which 24 were for primary treatment and 17 for recurrent disease. Of 24 patients who received bevacizumab as primary treatment, the median age was 52 years, and 12.5% of the patients had early-stage high-risk disease, 87.5% had FIGO stage III or IV disease, 45.8% had a serous adenocarcinoma, and 54.2% had residual disease after debulking surgery. Of 17 patients who received bevacizumab for recurrent disease, the median age was 52 years, and 94.1% of the patients were having their first recurrence, 64.7% had platinum-sensitive disease and 41.2% had a serous adenocarcinoma. Grade 2 or higher hypertension and proteinuria occured in 24.4% and 12.2% of patients, respectively. Bevacizumab was discontinued in 7.3% of patients due to adverse events and 31.7% due to inadequate therapeutic response. The median progression free survival was 18.0 months (95% CI 13.6 to 22.4) for primary treatment and 11.0 months (95% CI 8.4 to 13.6) for recurrent disease. Conclusions: With acceptable toxicity, combination of bevacizumab and chemotherapy may be considered as treatment modality in newly diagnosed suboptimally debulked stage III or stage IV ovarian cancer as well as in recurrent ovarian cancer.postprin

Emergency thrombectomy for acute ischaemic stroke: current evidence, international guidelines and local clinical practice

published_or_final_versio

An online pain education program for working adults : pilot randomized controlled trial

202006 bcrcVersion of RecordPublishe

A systematic review of nurse-led dietary interventions for cancer patients and survivors

202212 bckwVersion of RecordPublishe

The application of eyeglass displays in changing the perception of pain

We have been examining the potential value of visual stimulation via the eyeglass displays in changing the perception of pain. In this randomized, controlled, cross-over study, 72 healthy university student volunteers were asked to wear a light-weighted eyeglass projecting a feeling of watching a fifty-two-inch television screen in a close distance while pain was produced by a modified tourniquet technique. There is a significant increase of pain threshold and pain tolerance with the effect of visual stimulation. These findings having implications of using visual stimulation as positive adjunct to other methods of pain relief and to different pain conditions in clinical areas.link_to_subscribed_fulltex